LLY Stock Risk & Deep Value Analysis
Eli Lilly and Co
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
The Bottom Line on LLY
We analyzed Eli Lilly and Co using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran LLY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈LLY Performance Overview3yr weekly
Unlock LLY Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
LLY Stock Risk Analysis
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Low
About Eli Lilly and Co (LLY)
Sector
Healthcare
Industry
Drug Manufacturers - General
Market Cap Category
mega
Market Cap
$965.02B
LLY Deep Value Analysis
Compare LLY to Similar Stocks
See how Eli Lilly and Co stacks up against related companies in our head-to-head analysis.
LLY Red Flags & Warning Signs
Premium- ⚠
Stronger-than-expected competition in GLP-1 market from Novo Nordisk or new entrants
- ⚠
Unexpected clinical trial failures or regulatory setbacks for key pipeline candidates
- ⚠
Increased drug pricing pressure from governments or payers
- ⚠
Patent cliffs for current blockbuster drugs in the late 2020s/early 2030s
Unlock LLY Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
LLY Financial Health Metrics
Market Cap
$965.02B
P/E Ratio
52.64
LLY Competitive Moat Analysis
PremiumMoat Rating
Wide
Moat Trend
Expanding
Moat Sources
4 Identified
Eli Lilly's wide moat is durable due to its extensive patent portfolio covering blockbuster drugs, ongoing investment in a diverse R&D pipeline that consistently generates new intellectual property, significant manufacturing scale which creates cost advantages, and strong brand loyalty within the medical community. The high cost and complexity of drug development and regulatory approval also serve as substantial barriers to entry.
LLY Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
LLY Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated late Jan/early Feb 2026)
- •Key clinical trial readouts for pipeline assets (e.g., Donanemab for Alzheimer's, new GLP-1 indications)
- •Manufacturing capacity expansion updates for Mounjaro/Zepbound
Medium-Term (6-18 months)
- •Global market expansion for Mounjaro/Zepbound, including new geographies and indications
- •Progression of novel oncology or immunology assets through late-stage trials
- •Strategic partnerships to enhance R&D capabilities or market access
Long-Term (18+ months)
- •Sustained leadership in metabolic diseases and potential expansion into adjacent therapeutic areas
- •Successful commercialization of next-generation therapies, particularly in neuroscience
- •Leveraging AI and advanced analytics for drug discovery and development
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
LLY Bull Case: What Could Go Right
- ✓
Sustained double-digit sales growth of Mounjaro/Zepbound and successful expansion into new indications/geographies
- ✓
Positive clinical trial results and regulatory approvals for key pipeline candidates (e.g., Donanemab)
- ✓
Continued R&D productivity and successful advancement of next-generation therapies
Bull Case Analysis
See what could go right with Premium
Never miss a move on LLY
Create a free account to set price alerts and get notified on Telegram when LLY hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Eli Lilly and Co (LLY)?
As of January 22, 2026, Eli Lilly and Co has a DVR Score of 0.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Eli Lilly and Co?
Eli Lilly and Co's market capitalization is approximately $965.0B. The company operates in the Healthcare sector within the Drug Manufacturers - General industry.
What ticker symbol does Eli Lilly and Co use?
LLY is the ticker symbol for Eli Lilly and Co. The company trades on the NYQ.
What is the risk level for LLY stock?
Our analysis rates Eli Lilly and Co's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of LLY?
Eli Lilly and Co currently has a price-to-earnings (P/E) ratio of 52.6. This is above the market average, suggesting the stock may be priced for high growth expectations.
Does Eli Lilly and Co pay a dividend?
Yes, Eli Lilly and Co pays a dividend with a current yield of approximately 58.00%.
How often is the LLY DVR analysis updated?
Our AI-powered analysis of Eli Lilly and Co is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on January 22, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.